Prism Medico And Pharmacy Limited reported a profit of ₹31.84 lakh for the financial year ended March 31, 2026. The company also announced the proposed appointment of M/s. SDK & Associates as Secretarial Auditors for a five-year term. Other key resolutions included a variation in the objects of a preferential issue and an investment in equity shares of M/s. Infuze Well Private Limited.
Financial Performance for FY2025-2026
Prism Medico And Pharmacy Limited has released its financial results for the fiscal year ended March 31, 2026. The company achieved a profit of ₹31.84 lakh for the year. This contrasts with a loss of ₹4.87 lakh in the previous financial year. Revenue from operations stood at ₹244.34 lakh for the current fiscal year, up from ₹63.19 lakh in the prior year.
Key Corporate Actions
The company is proposing to appoint M/s. SDK & Associates, Practicing Company Secretaries, as its Secretarial Auditors for a period of five financial years, from 2026-2027 to 2030-2031. Shareholders will vote on this ordinary resolution during the upcoming Annual General Meeting (AGM).
Further, the agenda for the AGM includes a special resolution to approve a variation in the objects of the preferential issue and the utilization of its proceeds. This involves a strategic investment in M/s. Infuze Well Private Limited, which is expected to result in Prism Medico and Pharmacy Limited acquiring a controlling stake and making Infuze Well Private Limited a subsidiary.
The Board also recommended resolutions for approving the investment of funds in the securities of M/s. Infuze Well Private Limited, a material related party transaction, and other related party transactions, all subject to shareholder approval.
Director Re-appointment
Mr. Davender Singh, who retires by rotation, is offering himself for re-appointment as a Director at the ensuing AGM.
Source: BSE
